Author's response to reviews

Title: The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report

Authors:

Hye Sook Kim (hyesokim@gmail.com)
Seung Tae Kim (shty1@daum.net)
Seok Ho Kang (mdksh@korea.ac.kr)
Deuk Jae Sung (urorad@korea.ac.kr)
Chul Hwan Kim (chkap@korea.ac.kr)
Sang Won Shin (shinsw@kumc.or.kr)
Yeul Hong Kim (yhk0215@korea.ac.kr)
Won Yong Cho (wonyong@korea.ac.kr)
Kyong Hwa Park (khpark@korea.ac.kr)

Version: 2 Date: 22 July 2013

Author's response to reviews: see over
Dr. Michael Kidd
Editor-in-Chief of *Journal of Medical Case Reports*

Enclosed please find our manuscript entitled ‘The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report’, for the publication in *Journal of Medical Case Reports*. I would be very grateful if you would consider the manuscript by others (HS. Kim, ST Kim, SH Kang, DJ Sung, CH Kim, SW Shin, YH Kim, WY Cho) and me. We assure that your readers take a broad interest in this manuscript.

Despite recent advances in treatment of renal cell carcinoma (RCC), there is no validated predictive biomarker in selecting treatment. Here, we report the first case of adult patient with tuberous sclerosis complex (TSC) and RCC who had substantial benefit from everolimus. Considering genetic mutations in TSC result in upregulation of mammalian target of rapamycin (mTOR), this observation could provide a rationale for the use of everolimus as the first choice in this specific patient population to target right pathway for the carcinogenesis.

The content of our manuscript has not been published or submitted for publication elsewhere. All of the authors have read and agreed with the manuscript. Thank you for your kind attention to our manuscript.

Sincerely yours,

Kyong Hwa Park MD, PhD
Division of Oncology/Hematology
Department of Internal medicine
Korea University College of Medicine
73 Inchon-Ro, Sungbuk-gu, Seoul, Korea
Tel: +82-2-920-6841; FAX: +82-2-920-6520; E-mail: khpark@korea.ac.kr